UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

 

FORM 15

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g)
OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS
UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

Commission File Number  000-21589

 

 

Triangle Pharmaceuticals, Inc.

 

 

(Exact name of registrant as specified in its charter)

 

 

 

 

 

4 University Place

 

 

4611 University Drive

 

 

Durham, North Carolina 27707

 

 

(919) 493-5980

 

 

(Address, including zip code, and telephone number,
including area code, of registrant’s principal executive offices)

 

 

 

 

 

Common Stock par value $0.001 per share

 

 

(Title of each class of securities covered by this Form)

 

 

 

 

 

N/A

 

 

(Titles of all other classes of securities for which a duty to file
reports under Section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)(i)

 

ý

 

Rule 12h-3(b)(1)(i)

 

ý

 

Rule 12g-4(a)(1)(ii)

 

o

 

Rule 12h-3(b)(1)(ii)

 

o

 

Rule 12g-4(a)(2)(i)

 

o

 

Rule 12h-3(b)(2)(i)

 

o

 

Rule 12g-4(a)(2)(ii)

 

o

 

Rule 12h-3(b)(2)(ii)

 

o

 

 

 

 

 

Rule 15d-6

 

o

 

Approximate number of holders of record as of the certification or notice date:               One                          

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Triangle Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date:

January 24, 2003

 

By:

 

/s/ GREGG ALTON

 

 

 

 

 

Gregg Alton

 

 

 

 

 

Secretary